Comparative Pharmacology
Head-to-head clinical analysis: LIBERVANT versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBERVANT versus PAXIPAM.
LIBERVANT vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine
Benzodiazepine